<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01005862</url>
  </required_header>
  <id_info>
    <org_study_id>A9951011</org_study_id>
    <nct_id>NCT01005862</nct_id>
  </id_info>
  <brief_title>Effect of PF-04360365 On ABETA In Patients With Alzheimer's Disease And Healthy Volunteers</brief_title>
  <official_title>A Randomized, Investigator And Subject-Blind, Sponsor-Open, Placebo-Controlled Study To Examine The Effects Of PF-04360365 On ABETA In Patients With Alzheimer's Disease And Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of this study is to evaluate the effect of PF-04360365 on the clearance of
      ABETA from the CSF (cerebrospinal fluid) in patients with mild Alzheimer's disease and
      healthy volunteers. Additionally, the study will assess the pharmacokinetics of PF-04360365,
      pharmacokinetic and pharmacodynamic relationships in plasma and CSF and the safety and
      tolerability of single doses of PF-04360365 administered to patients with Alzheimer's disease
      and healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fractional Clearance rate of ABeta peptide in CSF</measure>
    <time_frame>36 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the ratio of CSF labeled/unlabeled ABETA time curve from onset of clearance to 36h following start of infusion</measure>
    <time_frame>36 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PF-04360365 concentrations and ABETA concentrations in plasma and CSF</measure>
    <time_frame>36 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of labeled/unlabeled leucine in plasma and CSF post labeled leucine administration</measure>
    <time_frame>36 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events, vital signs, clinical labs, electrocardiograms, physical / neurologic examinations, Columbia Suicide Severity Rating Scale, MRI</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>PF-04360365</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>single dose administered intravenously</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-04360365</intervention_name>
    <description>10 mg/kg, single dose administered intravenously</description>
    <arm_group_label>PF-04360365</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females of non-childbearing potential (age 50 and over for Alzheimer's
             disease patients; 21-45 for healthy volunteers)

          -  For patients with Alzheimer's Disease: Diagnosis of probable Alzheimer's disease,
             consistent with criteria from both National Institute of Neurological and Communicable
             Disease and Stroke and Alzheimer's Disease and Related Disorders Association
             (NINCDS-ADRDA) and Diagnostic and Statistical Manual of Mental Disorders (DSM IV)

          -  Mini-mental status exam score greater than or equal to 20

          -  Rosen-Modified Hachinski Ischemia Score of &lt; or = 4

          -  On stable dose of background cholinesterase inhibitor or memantine at least 3 months
             prior to enrollment

        Exclusion Criteria:

          -  Diagnosis or history of other demential or neurodegenerative disorders

          -  Diagnosis or history of clinically significant cerebrovascular disease

          -  Specific findings on magnetic resonance imaging (MRI); cortical infarct, micro
             hemorrhage, multiple white matter lacunes, extensive white matter abnormalities

          -  History of autoimmune disorders

          -  History of allergic or anaphylactic reactions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <zip>141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A9951011&amp;StudyName=Effect%20of%20PF-04360365%20On%20ABETA%20In%20Patients%20With%20Alzheimer%27s%20Disease%20And%20Healthy%20Volunteers</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2009</study_first_submitted>
  <study_first_submitted_qc>October 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2009</study_first_posted>
  <last_update_submitted>September 25, 2012</last_update_submitted>
  <last_update_submitted_qc>September 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's disease antibody leucine ABeta</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

